Joel Schlessinger

2.1k total citations · 1 hit paper
54 papers, 1.4k citations indexed

About

Joel Schlessinger is a scholar working on Dermatology, Neurology and Physiology. According to data from OpenAlex, Joel Schlessinger has authored 54 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Dermatology, 15 papers in Neurology and 12 papers in Physiology. Recurrent topics in Joel Schlessinger's work include Botulinum Toxin and Related Neurological Disorders (15 papers), Dermatologic Treatments and Research (14 papers) and Dermatology and Skin Diseases (9 papers). Joel Schlessinger is often cited by papers focused on Botulinum Toxin and Related Neurological Disorders (15 papers), Dermatologic Treatments and Research (14 papers) and Dermatology and Skin Diseases (9 papers). Joel Schlessinger collaborates with scholars based in United States, France and Canada. Joel Schlessinger's co-authors include Philip Werschler, Joel L. Cohen, Francisco A. Kerdel, David R. Adams, Alexa B. Kimball, Ulrich Mrowietz, Robert Gniadecki, Gregor B. E. Jemec, Hessel H. van der Zee and Parvez Mulani and has published in prestigious journals such as Annals of Internal Medicine, Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology.

In The Last Decade

Joel Schlessinger

49 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

2012 305 citations Alexa B. Kimball, Francisco A. Kerdel et al. Annals of Internal Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel Schlessinger United States	22	1.0k	477	314	285	160	54	1.4k
Rungsima Wanitphakdeedecha Thailand	26	1.6k 1.6×	395 0.8×	313 1.0×	150 0.5×	166 1.0×	134	2.1k
Moon Soo Yoon South Korea	20	274 0.3×	149 0.3×	217 0.7×	171 0.6×	134 0.8×	69	1.1k
Wolfgang G. Philipp‐Dormston Germany	20	784 0.8×	176 0.4×	238 0.8×	268 0.9×	39 0.2×	77	1.1k
Erick A. Mafong United States	12	490 0.5×	199 0.4×	139 0.4×	94 0.3×	50 0.3×	19	773
Vasanop Vachiramon Thailand	24	935 0.9×	134 0.3×	84 0.3×	196 0.7×	57 0.4×	97	1.5k
Arisa Ortiz United States	20	713 0.7×	188 0.4×	38 0.1×	228 0.8×	67 0.4×	53	1.2k
Miriam Weinstein Canada	15	183 0.2×	191 0.4×	125 0.4×	99 0.3×	56 0.3×	45	754
Marina Landau Israel	17	834 0.8×	177 0.4×	212 0.7×	67 0.2×	34 0.2×	64	1.1k
Rebecca Tung United States	18	628 0.6×	151 0.3×	218 0.7×	125 0.4×	42 0.3×	61	980
J.H. Sillevis Smitt Netherlands	22	509 0.5×	220 0.5×	59 0.2×	95 0.3×	202 1.3×	50	1.4k

Countries citing papers authored by Joel Schlessinger

Since Specialization

Citations

This map shows the geographic impact of Joel Schlessinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Schlessinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Schlessinger more than expected).

Fields of papers citing papers by Joel Schlessinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Schlessinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Schlessinger. The network helps show where Joel Schlessinger may publish in the future.

Co-authorship network of co-authors of Joel Schlessinger

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Schlessinger. A scholar is included among the top collaborators of Joel Schlessinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Schlessinger. Joel Schlessinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertucci, Vince, Joel Schlessinger, John Joseph, et al.. (2024). Efficacy and Safety of a Novel Formulation Liquid Botulinum Toxin, RelabotulinumtoxinA, When used for Combination Treatment of Glabellar and Lateral Canthal Lines. Toxicon. 237. 107369–107369. 1 indexed citations

Cohen, Joel L., Sue Ellen Cox, Dee Anna Glaser, et al.. (2024). A Review of Current Data on Duration of Effect in Glabellar Lines After Treatment With AbobotulinumtoxinA 50 U. Dermatologic Surgery. 50(9S). S5–S11.

Adelglass, Jeffrey, Rui L. Avelar, Leslie Baumann, et al.. (2021). The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients. Aesthetic Surgery Journal. 41(12). 1423–1438. 6 indexed citations

Cohen, Joel L., Mathew M. Avram, Renato Saltz, et al.. (2020). Aesthetic Office Disaster Preparedness and Response Plan. Journal of Drugs in Dermatology. 20(1). 10–16. 1 indexed citations

Schlessinger, Joel, Joel L. Cohen, Ava Shamban, et al.. (2020). A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines. Dermatologic Surgery. 47(4). 504–509. 19 indexed citations

Palm, Melanie D., et al.. (2019). Final Data from the Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR). PubMed. 18(1). 40–48. 10 indexed citations

Bertucci, Vince, Nowell Solish, Joely Kaufman‐Janette, et al.. (2019). DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology. 82(4). 838–845. 47 indexed citations

Baumann, Leslie, Andrew Blauvelt, Zoé Kececioglu Draelos, et al.. (2018). 465 A-101 (hydrogen peroxide) topical solution safety and efficacy in patients with seborrheic keratoses: Results from two identical randomized, double-blind, placebo-controlled, phase 3 studies. Journal of Investigative Dermatology. 138(5). S79–S79.

Baumann, Leslie, Andrew Blauvelt, Zoé Kececioglu Draelos, et al.. (2018). Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). Journal of the American Academy of Dermatology. 79(5). 869–877. 23 indexed citations

10.

Pariser, David M., Ellen Frankel, Joel Schlessinger, et al.. (2017). Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. Dermatology and Therapy. 8(1). 17–32. 15 indexed citations

11.

Hanke, C. William, Rhoda S. Narins, Fredric S Brandt, et al.. (2013). A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint. Dermatologic Surgery. 39(6). 891–899. 44 indexed citations

12.

Schlessinger, Joel, Jeffrey S. Dover, John Joseph, et al.. (2013). Long-Term Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines: Results From a 36-Month, Multicenter, Open-Label Extension Study. Dermatologic Surgery. 40(2). 176–183. 9 indexed citations

13.

Jewell, Mark L., Robert A. Weiss, Richard A. Baxter, et al.. (2012). Safety and Tolerability of High-Intensity Focused Ultrasonography for Noninvasive Body Sculpting: 24-Week Data From a Randomized, Sham-Controlled Study. Aesthetic Surgery Journal. 32(7). 868–876. 37 indexed citations

14.

Kimball, Alexa B., Francisco A. Kerdel, David R. Adams, et al.. (2012). Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine. 7 indexed citations

15.

Jewell, Mark L., Richard A. Baxter, Sue Ellen Cox, et al.. (2011). Randomized Sham-Controlled Trial to Evaluate the Safety and Effectiveness of a High-Intensity Focused Ultrasound Device for Noninvasive Body Sculpting. Plastic & Reconstructive Surgery. 128(1). 253–262. 58 indexed citations

16.

Schlessinger, Joel, Jeffrey M. Kenkel, & Philip Werschler. (2011). Further Enhancement of Facial Appearance With a Hydroquinone Skin Care System Plus Tretinoin in Patients Previously Treated With Botulinum Toxin Type A. Aesthetic Surgery Journal. 31(5). 529–539. 10 indexed citations

17.

Schlessinger, Joel, Gary D. Monheit, Michael A. C. Kane, & Naomi Mendelsohn. (2011). Time to Onset of Response of AbobotulinumtoxinA in the Treatment of Glabellar Lines: A Subset Analysis of Phase 3 Clinical Trials of a New Botulinum Toxin Type A. Dermatologic Surgery. 37(10). 1434–1442. 26 indexed citations

18.

Cohen, Joel L., Joel Schlessinger, Sue Ellen Cox, & Xiaoming Lin. (2009). An Analysis of the Long-Term Safety Data of Repeat Administrations of Botulinum Neurotoxin Type A-ABO for the Treatment of Glabellar Lines. Aesthetic Surgery Journal. 29(6). S43–S49. 25 indexed citations

19.

Schlessinger, Joel. (2008). Spa Dermatology: Past, Present, and Future. Dermatologic Clinics. 26(3). 403–411. 7 indexed citations

20.

Schlessinger, Joel, et al.. (2006). An Open-label Adrenal Suppression Study of 0.1% Fluocinonide Cream in Pediatric Patients With Atopic Dermatitis. Archives of Dermatology. 142(12). 1568–72. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact